ondansetron

(redirected from Zuplenz)
Also found in: Dictionary.

antiemetic

 [an″te-e-met´ik]
1. useful in the treatment of vomiting.
2. an agent that relieves vomiting.
Miller-Keane Encyclopedia and Dictionary of Medicine, Nursing, and Allied Health, Seventh Edition. © 2003 by Saunders, an imprint of Elsevier, Inc. All rights reserved.

ondansetron

(ŏn-dăn′sĭ-trŏn′)
n.
A selective serotonin receptor antagonist, C18H19N3O, used in its hydrochloride form to prevent nausea and vomiting, especially when occurring postoperatively or as a result of chemotherapy or radiotherapy.
The American Heritage® Medical Dictionary Copyright © 2007, 2004 by Houghton Mifflin Company. Published by Houghton Mifflin Company. All rights reserved.

ondansetron

Oncology A selective serotonin S3 receptor antagonist used to ameliorate chemotherapy-induced N&V. See Chemotherapy-induced emesis.
McGraw-Hill Concise Dictionary of Modern Medicine. © 2002 by The McGraw-Hill Companies, Inc.

ondansetron

A serotonin antagonist drug used to relieve nausea and vomiting caused by anticancer chemotherapy and radiotherapy and to prevent sickness after surgery. A brand name is Zofran.
Collins Dictionary of Medicine © Robert M. Youngson 2004, 2005
References in periodicals archive ?
Midatech said it expects that the acquisition of Zuplenz will leverage its commercial infrastructure in the United States, following the acquisition of DARA BioSciences, and is complementary to Midatech's three existing marketed oncology products.
Strativa Pharmaceuticals launched Oravig[R] and Zuplenz (ondansetron) in the second half of 2010 and records revenues on an as-prescribed basis.
Biopharmaceutical company Galena Biopharma (NasdaqCM:GALE) reported on Friday the launch of an agreement to divest its Zuplenz (ondansetron) Oral Soluble Film product to Midatech Pharma valued at up to USD29.75m.
Pharmaceutical company Midatech Pharma (LSE:MTPH.L) revealed on Thursday that it has entered into an agreement to acquire Zuplenz (ondansetron) for emetogenic chemotherapy-induced nausea and vomiting from Galena Biopharma (NasdaqCM:GALE) for a total up front consideration of USD3.75m in cash.
M2 EQUITYBITES-December 18, 2015-Midatech Pharma to buy Zuplenz from Galena Biopharma for USD3.75m in cash
It was reported yesterday that the contract has been signed to license the US rights for Zuplenz (ondansetron) oral soluble film.
This is the second US marketing authorisation for a prescription product based on MonoSol Rx's PharmFilm technology, closely following the July 2010 FDA approval of the anti-emetic Zuplenz (ondansetron) oral soluble film, MonoSol Rx said.
11 February 2010 - Strativa Pharmaceuticals, the proprietary products division of a wholly-owned subsidiary of Par Pharmaceutical Companies Inc (NYSE: PRX), said last Friday that the US Food and Drug Administration (FDA) has issued a Complete Response letter regarding the New Drug Application (NDA) for Zuplenz (ondansetron) oral soluble film for the prevention of nausea and vomiting associated with highly- and moderately-emetogenic chemotherapy, radiotherapy and surgery.
M2 EQUITYBITES-July 12, 2011-MonoSol Rx unveils anti-emetic Zuplenz oral soluble film for licensing to new commercial partners(C)2011 M2 COMMUNICATIONS http://www.m2.com
M2 EQUITYBITES-5 July 2010-Strativa Pharmaceuticals reports FDA approval for Zuplenz oral soluble film for prevention of chemotherapy-induced, radiotherapy-induced and postoperative nausea and vomiting(C)2010 M2 COMMUNICATIONS http://www.m2.com
Some of the popular brands of hyperemesis gravidarum treatment include Diclectin (Duchesnay Inc.), Pregvit (Duchesnay Inc.), Zofran (Novartis AG), Zuplenz (Midatech Pharma US Inc.), Kytril (Genentech, Inc.), etc.